Roche terminates phase 1 trial of RO7763505 in coronary artery disease
The study, which was testing the drug in healthy volunteers and stable CAD patients, was stopped with Roche citing discontinued development.
ClinicalTrials.gov
50 stories
The study, which was testing the drug in healthy volunteers and stable CAD patients, was stopped with Roche citing discontinued development.
ClinicalTrials.gov
Olema said it remains on track to report top-line results from its pivotal Phase 3 OPERA-01 trial of palazestrant in the first quarter of 2027, while enrollment continues in a second pivotal trial and an early-stage.
FDA, SEC filing (2)
Iambic highlighted updated IAM1363 data at ESMO, a new IAM217 Safe-to-Proceed letter, and a pro forma cash position of about $455 million after its October IPO.
Drugs@FDA, FDA, SEC filing (3)
The agency authorized obinutuzumab injection to induce remission of proteinuria in adults with the kidney disease who face risk of progression.
FDA, Drugs@FDA (2)
The company said patient visits in its Phase 1b Alzheimer's trial are closing out, with cash of $44.1 million expected to fund operations through 2027.
SEC filing
Eikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.
SEC filing (12)
The agency granted accelerated approval for entrectinib in younger children with NTRK fusion-positive solid tumors and authorized a new dosage form.
FDA
The voucher is intended to support a future filing in BioNTech's late-stage oncology pipeline, pending customary closing conditions.
SEC filing
Patrick Vink stepped down from Spero's board effective November 10, 2026, and William Ho was appointed to fill the vacancy the same day.
SEC filing
The company initiated two new oncology studies in October and November and said a first-line zipalertinib NDA submission is expected to complete in November.
SEC filing (3)
Zymeworks reported third-quarter 2026 results, raised full-year revenue and EBITDA guidance, and detailed a new Roche collaboration on ZW209 pending antitrust clearance.
SEC filing
The approval covers use after tumor resection in patients with ALK-positive non-small cell lung cancer identified by an FDA-approved test.
FDA
The agency cleared capivasertib with abiraterone and prednisone for PTEN-deficient, androgen pathway modulation-naïve or -sensitive metastatic prostate cancer.
FDA (6)
The approval covers adults with recurrent or metastatic HNSCC that progressed after platinum chemotherapy and an anti-PD-(L)1 antibody, based on tumor response data.
FDA press release, FDA, Drugs@FDA (10)
GeoVax Labs seeks net proceeds of about $4.6 million in a Nasdaq offering tied to a Phase 3 GEO-MVA trial, while Xbrane's ranibizumab approval remains unchanged.
Drugs@FDA, SEC filing (2)
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Cheng Liu moves from CEO to Chief Scientific Officer while remaining President and a director, the company said in an October 29, 2026 filing.
SEC filing
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)
Ionis partner Roche said sefaxersen lowered proteinuria 43.1% versus placebo at 37 weeks in the Phase 3 IMAgINATION study, with safety consistent with Phase 2.
SEC filing
Zymeworks will get $55 million upfront plus up to $758 million in milestones and tiered royalties as Roche takes over global rights to the trispecific T cell engager.
SEC filing
The Nasdaq-listed company said Wong will start as VP and principal accounting officer on November 2, 2026, with a base salary of $360,000.
SEC filing
The October 20, 2026 deal gives Imunon equity, milestone payments up to $16.5 million, and royalties, while it keeps focus on its Phase 3 OVATION 3 trial.
SEC filing (5)
The antisense oligonucleotide, given with existing antiviral therapy, lets some adults stop all HBV treatment and keep the virus under control.
SEC filing, Drugs@FDA, FDA, FDA press release (6)
Alector plans an October 13 webinar on its anti-Abeta, tau, and alpha-synuclein programs following its $100 million upfront Genentech license and updated cash guidance into 2029.
SEC filing (5)
The company plans to resubmit an FDA application by the end of 2026 after the trial met both co-primary endpoints and all secondary endpoints.
SEC filing
The phase II study, sponsored by MD Anderson with NCI and Genentech as collaborators, was terminated after failing to reach enrollment targets, according to its ClinicalTrials.gov record.
ClinicalTrials.gov
The agency approved an eighth supplement to satralizumab's biologics license, according to FDA records dated October 15, 2026.
Drugs@FDA
Nurix dosed its first patient in a registrational Phase 3 CLL trial for bexobrutideg, discontinued NX-2127, and ended the quarter with $1.1 billion in cash after closing its Roche collaboration.
SEC filing
The agency's approval covers adjuvant use of the immunotherapy alongside chemotherapy in patients as young as two.
Drugs@FDA, FDA (2)
The agency cleared an efficacy supplement for the atezolizumab injection under priority review, with a status date of October 8, 2026.
Drugs@FDA
The FDA cleared supplement 43 to Gazyva's biologics license on September 25, 2026, though the agency's record does not detail the specific change.
Drugs@FDA
The IMAgINATION study hit its primary endpoint at 37 weeks, with the trial continuing blinded to assess kidney function through week 105.
SEC filing